PubRank

N Hollander

Author PubWeight™ 30.06‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Heterogeneous mutations in the beta subunit common to the LFA-1, Mac-1, and p150,95 glycoproteins cause leukocyte adhesion deficiency. Cell 1987 2.23
2 Blocking effect of lyt-2 antibodies on T cell functions. J Exp Med 1980 2.15
3 The CD48 receptor mediates Staphylococcus aureus human and murine eosinophil activation. Clin Exp Allergy 2014 1.98
4 Adipose-cell size and immunoreactive insulin levels in obese and normal-weight adults. Lancet 1972 1.61
5 Environmental enrichment in mice decreases anxiety, attenuates stress responses and enhances natural killer cell activity. Eur J Neurosci 2004 1.51
6 The development of hypersensitive lymphocytes in cell culture. J Exp Med 1971 1.11
7 Effects of Lyt antibodies on T-cell functions: augmentation by anti-Lyt-1 as opposed to inhibition by anti-Lyt-2. Proc Natl Acad Sci U S A 1981 1.10
8 The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 1984 1.08
9 Allogeneic cytolysis of reconstituted membrane vesicles. Proc Natl Acad Sci U S A 1979 0.98
10 Effects of anti-Lyt antibodies on T-cell functions. Immunol Rev 1982 0.95
11 The effect of cytochalasin B on effector--target cell interaction. Quantitative and ultrastructural study. Immunology 1975 0.94
12 In vitro generation of memory lymphocytes reactive to transplantation antigens. J Exp Med 1974 0.90
13 Specific adherence of in vitro differentiated lymphocytes to target cells. J Exp Med 1972 0.88
14 Seroprevalence of toxoplasma antibody in a Toronto population. Can J Infect Dis 1996 0.86
15 Lysis and necrosis: analysis of two cytotoxic phenomena mediated by lymphocytes. Isr J Med Sci 1976 0.86
16 Purification and characterization of tumor inhibitory factor-2: its identity to interleukin 1. Cancer Res 1989 0.84
17 Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma. Clin Exp Immunol 2012 0.82
18 Cleavage of the glycosylphosphatidylinositol anchor affects the reactivity of thy-1 with antibodies. J Immunol 1999 0.81
19 Immunotherapy of lymphoid and nonlymphoid tumors with monoclonal anti-Lyt-1 antibodies. J Immunol 1984 0.80
20 In vitro binding of cortisol-1,2-3H by a substance in the supernatant fraction of P1798 mouse lymphosarcoma. Biochem Biophys Res Commun 1966 0.79
21 Physical abuse as a predictor of child homicide. Tex Med 1986 0.79
22 Normal and neoplastic lymphocyte maturation. J Supramol Struct Cell Biochem 1981 0.79
23 Expression of L-selectin and efficient binding to high endothelial venules do not modulate the dissemination potential of murine B-cell lymphoma. Cancer Immunol Immunother 2001 0.79
24 The glycosylphosphatidylinositol-anchored form and the transmembrane form of CD58 associate with protein kinases. J Immunol 1998 0.78
25 Antibodies to nonpolymorphic determinants of the Thy-1 molecule inhibit T cell proliferation. J Immunol 1985 0.78
26 Lyt-2+ suppressor T cells are resistant to anti-Lyt-2 antibody blocking. J Immunol 1985 0.77
27 Light chain loss and reexpression leads to idiotype switch. Surrogate light chains are probably responsible for this process. Curr Top Microbiol Immunol 1995 0.77
28 The glycosylphosphatidylinositol-anchored form and the transmembrane form of CD58 are released from the cell surface upon antibody binding. Cell Immunol 1998 0.76
29 The functional association of Lyt antigens with lymphokine production. Immunology 1985 0.75
30 Effect of anti-theta serum on target cell lysis produced by lymphocytes stimulated with pokeweed mitogen. Transplantation 1973 0.75
31 An immunoregulatory factor associated with spleen cells from tumor-bearing animals. I. Effect on tumor growth and antibody production. Int J Cancer 1978 0.75
32 Development of a somatotropic variant of the mammosomatotropic tumor MtT-W5. Proc Soc Exp Biol Med 1971 0.75
33 Reimbursing hospice care: a Blue Cross and Blue Shield perspective. Hosp Prog 1979 0.75
34 Idiotype-specific inhibition of LFA-1-mediated cell adhesion by anti-idiotype x anti-LFA-1 bispecific antibodies. Immunol Lett 1998 0.75
35 An immunoregulatory factor associated with spleen cells from tumor-bearing animals. III. Characterization of the factor's target cells. Int J Cancer 1979 0.75
36 The cost of AIDS: who will pay? Pa Med 1990 0.75
37 Air crash disaster planning. Am J Forensic Med Pathol 1987 0.75
38 Deaths in infants and children. The importance of correct certification of the manner of death. Am J Forensic Med Pathol 1989 0.75
39 Rejection of tumors of the B cell lineage by idiotype-vaccinated mice. Cancer Immunol Immunother 1999 0.75
40 Experts probe issues around hospice care. Hospitals 1980 0.75
41 Relation between cortisol metabolism and its lympholytic effect in P1798 lymphosarcoma. Endocrinology 1966 0.75
42 The immunotherapeutic effect of anti Lyt-1 antibodies on local and metastatic tumor growth. Adv Exp Med Biol 1985 0.75
43 A synergistic effect between anti-idiotype antibodies and anti-neoplastic drugs in the therapy of a murine B-cell tumor. Int J Cancer 1986 0.75
44 An immunoregulatory factor associated with spleen cells from tumor-bearing animals. II. Characterization of the cell populations involved in its production and release. Int J Cancer 1978 0.75
45 Thy-1-negative and Ly-1-negative variants of T cells produce interleukin 2 in response to mitogens. J Immunol 1987 0.75
46 Homicides of abused children prematurely returned home. Forensic Sci Int 1986 0.75
47 Are small firms greater health risks? Health Aff (Millwood) 1995 0.75